MTHFR genotype and colorectal adenoma recurrence: Data from a double-blind placebo-controlled clinical trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2409-2415

  Levine, A Joan ^a   Wallace, Kristin ^b   Tsang, Shirley ^c   Haile, Robert W ^a   Saibil, Fred ^d   Ahnen, Dennis ^e   Cole, Bernard F ^g   Barry, Elizabeth L ^b   Munroe, David J ^c   Ali, Iqbal U ^c   Ueland, Per ^f   Baron, John A ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF BERGEN   (Norway)

^g University of Vermont ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ENZYME VARIANT; FOLIC ACID; PLACEBO;

ADULT; ALLELE; ARTICLE; CANCER RECURRENCE; CANCER RISK; COLORECTAL ADENOMA; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DIET SUPPLEMENTATION; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT;

ADENOMA; ALLELES; ASPIRIN; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; LINEAR MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLACEBOS; POLYMORPHISM, GENETIC;

EID: 53349176780     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2670     Document Type: Article

References (35)

1. Hoffman RM. Altered methionine metabolism and transmethylation in cancer. Anticancer Res 1985;5:1-30.
2. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000;71:121-38.
3. Eto I, LKC. Essential Nutrients in Carcinogenesis. New York: Academic Press; 1996.
4. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993;85:875-84.
5. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 2002;132:2350-5S.
6. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-102.
7. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
8. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
9. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A 2001;98:14853-8.
10. Kono S, Chen K. Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci 2005;96:535-42.
11. Little J, Sharp L, Duthie S, Narayanan S. Colon cancer and genetic variation in folate metabolism: the clinical bottom line. J Nutr 2003;133:3758-66S.
12. Huang Y, Han S, Li Y, Mao Y, Xie Y. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet 2007;52:73-85.
13. Levine AJ, Siegmund KD, Ervin CM, et al. The methylenetetrahydrofolate reductase 677C->T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2000;9:657-63.
14. Marugame T, Tsuji E, Kiyohara C, et al. Relation of plasma folate and methylenetetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int J Epidemiol 2003;32:64-6.
15. Chen J, Giovannucci EL, Hunter DJ. MTHFR polymorphism, methylreplete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. J Nutr 1999;129:560-4S.
16. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev 1999;8:659-68.
17. Chen J, Giovannucci E, Hankinson SE, et al. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 1998;19:2129-32.
18. Martinez ME, Thompson P, Jacobs ET, et al. Dietary factors and biomarkers involved in the methylenetetrahydrofolate reductase genotype-colorectal adenoma pathway. Gastroenterology 2006;131:1706-16.
19. Weisberg IS, Jacques PF, Selhub J, et al. The 1298A->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001;156:409-15.
20. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 2004;159:423-43.
21. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007;297:2351-9.
22. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
23. Cole BF, Baron JA, Sandler RS, et al. A randomised trial of folic acid to prevent colorecta adenomas [abstract]. AACR 96th Annual Meeting 2005.
24. Gibson CS, MacLennan AH, Dekker GA, et al. Genetic polymorphisms and spontaneous preterm birth. Obstet Gynecol 2007;109:384-91.
25. Chango A, Boisson F, Barbe F, et al. The effect of 677C->T and 1298A->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000;83:593-6.
26. van der Put NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
27. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4.
28. Hirose M, Kono S, Tabata S, et al. Genetic polymorphisms of methylenetetrahydrofolate reductase and aldehyde dehydrogenase 2, alcohol use and risk of colorectal adenomas: Self-Defense Forces Health Study. Cancer Sci 2005;96:513-8.
29. Giovannucci E, Chen J, Smith-Warner SA, et al. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2003;12:970-9.
30. Boyapati SM, Bostick RM, McGlynn KA, et al. Folate intake, MTHFR C677T polymorphism, alcohol consumption, and risk for sporadic colorectal adenoma (United States). Cancer Causes Control 2004;15:493-501.
31. Ulvik A, Evensen ET, Lien EA, et al. Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am J Med Genet 2001;101:246-54.
32. Marugame T, Tsuji E, Inoue H, et al. Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas. Cancer Lett 2000;151:181-6.
33. Hubner RA, Muir KR, Liu JF, et al. Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence. Cancer Epidemiol Biomarkers Prev 2006;15:1607-13.
34. van den Donk M, Buijsse B, van den Berg SW, et al. Dietary intake of folate and riboflavin, MTHFR C677T genotype, and colorectal adenoma risk: a Dutch case-control study. Cancer Epidemiol Biomarkers Prev 2005;14:1562-6.
35. Wilson A, Platt R, Wu Q, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999;67:317-23.